Retatrutide
$140.00
Item number:
1
Retatrutide (often shortened to "Reta") is an investigational "triple-agonist" drug (targeting GLP-1, GIP, and glucagon receptors) showing potential for superior, rapid weight loss (up to 24–28% in trials), improved blood sugar control, significant reductions in visceral and liver fat, and improved heart health markers. It also offers potential benefits for treating fatty liver disease, reducing joint pain, and managing PCOS, while being administered weekly.
Retaturtid peptide, research-grade peptide widely used in metabolic and wellness studies.
Specifications
•Specification: 1 vial
•Purity: ≥ 99%
•Form: Lyophilized powder
- Substantial Weight Loss: Clinical trials showed that higher doses of Retatrutide could resulted in a 22–24% reduction in body weight over 48 weeks
- Triple-Action Mechanism: Unlike dual-agonists, it targets three receptors (GLP-1, GIP, and Glucagon) to not only suppress appetite and increase fullness but also to boost energy expenditure (calorie burning).
- Improved Metabolic Health: Beyond weight loss, it significantly improves insulin sensitivity, lowers blood pressure, and improves lipid profiles.
- Liver and Joint Health: It shows high efficacy in reducing fat in the liver (89–93% of participants in trials reached healthy levels) and can alleviate joint pain due to weight reduction.
- Muscle-Sparing Potential: Initial data suggests it may preserve lean muscle mass better than some earlier-generation weight-loss medications.
- Reduced Cravings: Participants often report significantly reduced food cravings and more stable energy levels
FOR RESEARCH PERPOSES ONLY - NOT INTENDED FOR HUMAN USE